The stimulator of interferon genes pathway serves as a master regulator of innate anti-tumor immunity. However, hostile microenvironmental pressures often impair this critical immune defense mechanism. Recent breakthrough research reveals that STING K370 lactylation represents a vital metabolic checkpoint that directly suppresses innate immune surveillance. High glycolytic turnover in malignant tissue generates excess lactate, which chemically alters STING at lysine 370. Consequently, this primate-conserved post-translational modification dampens interferon production and promotes tumor progression.

Understanding STING K370 Lactylation in Tumor Biology

Solid tumors frequently alter their glucose metabolism to prioritize aerobic glycolysis, commonly known as the Warburg effect. This metabolic adaptation floods the extracellular and intracellular microenvironments with high concentrations of lactic acid. Historically, clinicians viewed lactate merely as a metabolic waste product. Today, researchers recognize lactate as an active signaling molecule that orchestrates post-translational protein lactylation.

Importantly, investigators identified that lactate triggers specific lactylation of STING at the primate-conserved lysine 370 residue. This metabolic modification acts as an off-switch for innate cytosolic DNA sensing. When malignant cells induce STING K370 lactylation, host immune cells fail to detect tumor-derived genetic fragments efficiently. Therefore, this post-translational modification creates an immunosuppressive protective barrier around malignant lesions, allowing malignant clones to evade immune-mediated destruction.

Disruption of STING-TBK1 Binding and Signal Transduction

Under physiological conditions, cyclic dinucleotide activation prompts STING to recruit TANK-binding kinase 1. This catalytic interaction facilitates downstream phosphorylation events that drive robust type I interferon expression. However, the accumulation of lactate dramatically perturbs this foundational protein interaction.

Specifically, lactylation at lysine 370 directly impairs the physical interface between STING and TBK1. Because the lactyl group adds steric bulk and alters local surface electrostatics, TBK1 cannot bind efficiently to the STING C-terminal tail. Consequently, downstream phosphorylation of interferon regulatory factor 3 drops significantly. As a result, malignant cells suppress the transcription of vital pro-inflammatory chemokines and interferons, crippling cytotoxic T cell recruitment.

Ubiquitin Linkage Rewiring and Protein Destabilization

Beyond blocking kinase recruitment, lactate-mediated modification fundamentally alters STING post-translational turnover. Normally, functional activation of STING relies on specific ubiquitin linkages that govern assembly and degradation. Active signaling requires K63-linked polyubiquitination to promote macromolecular oligomerization and downstream platform assembly.

Remarkably, lactylation at the K370 residue rewires the ubiquitin linkage preference of STING. The modification significantly decreases positive K63-linked ubiquitination while accelerating destructive K48-linked polyubiquitination. Because K48 ubiquitin chains deliver proteins directly to the 26S proteasome, STING undergoes accelerated intracellular degradation. Therefore, lactylation shortens the functional half-life of STING, preventing the sustained signaling bursts needed to prime robust anti-tumor immunity.

Impairment of SEC24A-Mediated ER-to-Golgi Trafficking

Spatial positioning represents another crucial checkpoint in the activation of the cGAS-STING cascade. After binding cyclic dinucleotides, STING must translocate from the endoplasmic reticulum to the Golgi apparatus. This spatial journey requires active packaging into coat protein complex II vesicles through direct binding to SEC24A.

Crucially, K370 modification weakens the physical interaction between STING and the COPII cargo adapter SEC24A. Without effective SEC24A engagement, STING remains trapped within the endoplasmic reticulum membrane network. Because ER-to-Golgi trafficking provides the essential spatial platform to amplify TBK1 phosphorylation, vesicle stagnation entirely paralyzes downstream cascades. Thus, metabolic lactylation disables both the spatial movement and enzymatic activation of STING.

Targeting LDHA to Overcome Immunotherapy Resistance

Fortunately, preclinical investigations show that blocking lactate generation effectively reverses these immunosuppressive molecular defects. Pharmacological inhibition of lactate dehydrogenase A rapidly depletes intracellular lactate pools. Consequently, this metabolic intervention abolishes aberrant K370 lactylation on the STING protein.

Once clinicians reduce lactate production, STING regains its native ability to bind SEC24A and move toward the Golgi apparatus. Furthermore, normal ubiquitin homeostasis returns, stabilizing the sensor against premature proteasomal degradation. Most importantly, restoring STING-TBK1 physical association reactivates type I interferon gene expression. Therefore, LDHA inhibition converts immunologically cold microenvironments into highly inflamed, responsive tissues.

Translational Potential in Glioblastoma and Combination Regimens

These mechanistic insights provide strong translational rationale for novel oncology drug combinations. In aggressive preclinical models, such as orthotopic glioblastoma and patient-derived xenografts, single-agent STING agonists frequently trigger adaptive resistance. However, combining pharmacological LDHA inhibitors with STING agonists yields dramatic therapeutic synergy.

Additionally, combining metabolic lactate blockade with anti-PD-1 checkpoint inhibitors unleashes potent CD8-positive T cell responses. This tripartite strategy eliminates primary tumors and establishes durable immunological memory in experimental systems. Consequently, targeting lactate metabolism represents a promising avenue to enhance immunotherapy response rates in treatment-refractory human cancers.

What is the functional role of STING K370 lactylation in cancer?

STING K370 lactylation acts as an immunosuppressive metabolic checkpoint. High lactate levels within tumors promote the covalent modification of STING at lysine 370. This alteration prevents STING from binding to TBK1 and accelerates proteasomal degradation. Consequently, tumor cells blunt type I interferon production, suppress cytotoxic T cell infiltration, and evade host immune surveillance.

How does lactate-induced modification impair intracellular STING trafficking?

To initiate productive immune signaling, STING must translocate from the endoplasmic reticulum to the Golgi apparatus using COPII vesicles. Lactylation at lysine 370 disrupts the binding interface between STING and the COPII subunit SEC24A. Without SEC24A interaction, STING remains trapped in the endoplasmic reticulum, which prevents necessary downstream phosphorylation cascades.

Why is LDHA inhibition combined with STING agonists therapeutically promising?

STING agonists often show limited single-agent efficacy due to tumor-driven lactate immunosuppression. Pharmacological inhibition of LDHA lowers microenvironmental lactate, preventing K370 lactylation and stabilizing STING expression. Consequently, combining LDHA inhibitors with STING agonists and anti-PD-1 antibodies restores robust interferon synthesis and significantly enhances anti-tumor immunity in resistant malignancies.

Disclaimer: This content is for informational and educational purposes only and should not be considered medical advice. Always consult a qualified healthcare professional regarding any medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.

References

1. Wu Y et al. Lactate-Induced K370 Lactylation of STING Inhibits STING-TBK1 Signaling and Dampens Anti-Tumor Immunity. Adv Sci (Weinh). 2026 Aug 15. doi: 10.1002/advs.77209. PMID: 42603295.

2. Zhang D, Tang Z, Huang H, et al. Metabolic regulation of gene expression by histone lactylation. Nature. 2019;574(7779):575-580.

3. Barber GN. STING: infection, inflammation and cancer. Nat Rev Immunol. 2015;15(12):760-770.